Taigen Biopharmaceuticals Holdings Limited announced earnings results for the third quarter ended September 30, 2018. For the third quarter, the company announced sales was TWD 4.954 million compared to TWD 8.140 million a year ago. Operating loss was TWD 66.743 million compared to TWD 69.341 million a year ago. Net loss was TWD 124.573 million compared to TWD 43.718 million a year ago. Basic loss per share was TWD 0.17 compared to TWD 0.06 a year ago. Diluted eps was TWD 0 compared to diluted loss per share of TWD 0.06 a year ago. For the nine months, sales was TWD 24.932 million compared to TWD 550.584 million a year ago. Operating loss was TWD 174.330 million compared to operating Income of TWD 332.978 million a year ago. Net loss was TWD 247.460 million compared to net income of TWD 877.233 million a year ago. Basic loss per share was TWD 0.35 compared to basic earnings per share of TWD 1.22 a year ago. Diluted eps was TWD 0 compared to TWD 1.22 a year ago.